Neurogene Inc. (NGNE)
| Market Cap | 435.18M +57.5% |
| Revenue (ttm) | n/a |
| Net Income | -98.64M |
| EPS | -4.56 |
| Shares Out | 15.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,319 |
| Open | 27.56 |
| Previous Close | 27.54 |
| Day's Range | 27.14 - 29.20 |
| 52-Week Range | 14.65 - 37.27 |
| Beta | 2.08 |
| Analysts | Strong Buy |
| Price Target | 80.00 (+190.49%) |
| Earnings Date | May 12, 2026 |
About NGNE
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for NGNE stock is "Strong Buy." The 12-month stock price target is $80.0, which is an increase of 190.49% from the latest price.
News
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
Cash, cash equivalents and short-term investments as of March 31, 2026 were $243.2 million and are expected to fund planned operations through the first quarter of 2028. “The significant unmet…
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Quarterly report: Q1 2026
Neurogene has published its Q1 2026 quarterly earnings report on May 12, 2026.
Neurogene Earnings release: Q1 2026
Neurogene released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, hig...
Neurogene Slides: Corporate presentation
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on May 11, 2026.
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene to present on ICV delivery in CNS-targeted gene therapy
Neurogene (NGNE) announced an upcoming poster presentation that will demystify the intracerebroventricular route of administration as a well-established, routinely performed neurosurgical procedure an...
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Neurogene (NGNE) with a Buy rating and $69 price target
Neurogene appoints Christy Shafer as CCO
Neurogene (NGNE) announced the appointment of Christy Shafer as Chief Commercial Officer and the appointment of Christine Mikail, president and CFO, to its Board of Directors. Shafer most recently ser...
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Proxy statement: Proxy filing
Neurogene filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Neurogene Proxy statement: Proxy filing
Neurogene filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Neurogene price target lowered to $180 from $200 at Canaccord
Canaccord lowered the firm’s price target on Neurogene (NGNE) to $180 from $200 and keeps a Buy rating on the shares. The firm updated its model for 4Q25 results, company…
Neurogene reports FY25 EPS ($4.24) vs ($4.28) last year
“We continue to demonstrate strong execution, with completion of enrollment in the Embolden registrational trial, dosing more than half of participants, and receipt of Breakthrough Therapy designation...
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Annual report: Q4 2025
Neurogene has published its Q4 2025 annual report on March 24, 2026.
Neurogene Earnings release: Q4 2025
Neurogene released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Neurogene Slides: Corporate presentation
Neurogene has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
Neurogene Transcript: Stifel 2026 Virtual CNS Forum
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...
Neurogene Transcript: Leerink Global Healthcare Conference 2026
NGN-401 is advancing in a pivotal trial for Rett syndrome, with durable, multi-domain functional gains observed and a 12-month endpoint required for approval. Commercial launch will leverage in-house manufacturing and a network of US centers, with Europe as a future opportunity.
Neurogene Transcript: TD Cowen 46th Annual Health Care Conference
NGN-401, a gene therapy for Rett syndrome, is advancing with strong clinical data showing multi-domain developmental gains and an 80% responder rate. Enrollment for the pivotal Embolden trial is on track for Q2 completion, with safety protocols in place and long-term durability data prioritized.
Canaccord starts Neurogene with Buy rating, $200 price target
Canaccord initiated coverage of Neurogene (NGNE) with a Buy rating and $200 price target The stock in premarket trading is up 34%, or $6.71, to $26.39. Neurogene is a clinical-stage…